by Dante J. Pieramici, MD
Dante J. Pieramici, MD, from California Retina Consultants in Santa Barbara, provides a summary of the data from the HORIZON extension study on variable dosing schedules with ranibizumab.
980 video views and 24,241 series views since 8/15/2011
-
Inherited Retinal Diseases
-
Thrombogenic Phase 3 Ocriplasmin Study
-
Achieving Water-tight Sclerotomies after 23G Surgery
-
PACORES Update
-
Sclerally-fixated IOLs Without Sutures
-
Does Suturing 23-Gauge Sclerotomies Reduce Postop Vitreous Hemorrhage in Di…
-
Modified Probe for Small-gauge Vitrectomy
-
The Role of Scissors in Diabetic Traction Retinal Detachment Surgery
-
Fine Needle Aspiration Biopsy
-
Adjunctive Steroids for Small-gauge Vitrectomy
-
COPERNICUS
-
Ranibizumab Variable Dosing: Horizon Extension Data
-
Dexamethasone Implant Plus Laser vs Laser Monotherapy
-
Ocriplasmin Phase 3 Data
-
Pneumatic Retinopexy, Pars Plana Vitrectomy, and Scleral Buckling
-
FAME Subanalyses
-
DA VINCI
-
Allen Ho, MD, Reviews Highlights of Upcoming Retina Meeting
-
Dean Eliott, MD, Reviews Highlights of Upcoming Retina Meeting
